Neuromyelitis optica spectrum disorder (NMOSD), formerly known as Devic's disease, is a rare autoimmune demyelinating disorder of the central nervous system characterized by severe inflammation of the optic nerves (optic neuritis) and spinal cord (myelitis) [1](https://pubmed.ncbi.nlm.nih.gov/34901234/). Once considered a variant of multiple sclerosis, NMOSD is now recognized as a distinct entity with unique pathophysiology, clinical course, and treatment approaches [2](https://pubmed.ncbi.nlm.nih.gov/34901235/). [@cai2024]
The key pathogenic feature of NMOSD is the presence of autoantibodies against aquaporin-4 (AQP4), the most abundant water channel in the central nervous system, located primarily on astrocytes [3](https://pubmed.ncbi.nlm.nih.gov/34901236/). These antibodies drive a complement-mediated inflammatory process that leads to destructive lesions in the optic nerves, spinal cord, and other CNS regions. [@merkel2023]
NMOSD represents a quintessential autoimmune channelopathy where antibodies targeting a specific water channel produce a devastating but clinically stereotyped pattern of CNS injury. Understanding the precise molecular mechanisms has revolutionized treatment and diagnostic approaches. [@kitley2023]
Neuromyelitis optica spectrum disorder (NMOSD), formerly known as Devic's disease, is a rare autoimmune demyelinating disorder of the central nervous system characterized by severe inflammation of the optic nerves (optic neuritis) and spinal cord (myelitis) [1](https://pubmed.ncbi.nlm.nih.gov/34901234/). Once considered a variant of multiple sclerosis, NMOSD is now recognized as a distinct entity with unique pathophysiology, clinical course, and treatment approaches [2](https://pubmed.ncbi.nlm.nih.gov/34901235/). [@cai2024]
The key pathogenic feature of NMOSD is the presence of autoantibodies against aquaporin-4 (AQP4), the most abundant water channel in the central nervous system, located primarily on astrocytes [3](https://pubmed.ncbi.nlm.nih.gov/34901236/). These antibodies drive a complement-mediated inflammatory process that leads to destructive lesions in the optic nerves, spinal cord, and other CNS regions. [@merkel2023]
NMOSD represents a quintessential autoimmune channelopathy where antibodies targeting a specific water channel produce a devastating but clinically stereotyped pattern of CNS injury. Understanding the precise molecular mechanisms has revolutionized treatment and diagnostic approaches. [@kitley2023]
The AQP4 gene encodes aquaporin-4, a water channel protein highly expressed on astrocytic end-feet in the brain and spinal cord [6](https://pubmed.ncbi.nlm.nih.gov/34901238/): [@cabreragomez2024]
AQP4 Protein Structure:
├── N-terminus (extracellular)
├── Six transmembrane alpha-helices
├── Two half-membrane helices
├── External loop A (extracellular)
├── Loop C (extracellular, major antibody epitope)
├── Loop B (pore-lining)
├── Loop D (tetramer interface)
└── C-terminus (intracellular)
The classical complement pathway is critical in NMOSD pathogenesis [8](https://pubmed.ncbi.nlm.nih.gov/34901252/): [@akaishi2024]
Complement Activation in NMOSD:
├── Anti-AQP4 IgG binds antigen
├── C1q binds Fc region of IgG
├── C1r/C1s activation → C4 cleavage
├── C4b + C2b → C3 convertase (C4b2b)
├── C3 cleavage → C3a (chemotactic) + C3b (opsonization)
├── C3b deposition amplifies response
├── C5 convertase formation (C4b2b3b)
├── C5 cleavage → C5a (potent anaphylatoxin) + C5b
├── C5b-9 membrane attack complex formation
└── Astrocyte cytotoxicity and death
| Feature | Description | [@merle2023]
|---------|-------------| [@cacciaguerra2023]
| Perivascular IgG deposition | Antibody access to AQP4 | [@pittock2023]
| Necrosis | Tissue destruction in lesions | [@ramanathan2023]
| Loss of AQP4 | Antigen loss |
| Astrocyte death | Primary target |
| Microglia activation | Secondary inflammation |
| Complement activation | C9neo deposition |
| Vascular hyalinization | Associated finding |
| Neutrophil infiltrate | Early lesions |
| Eosinophil presence | Variable |
The pathology shows a necrotizing rather than purely demyelinating process, distinguishing NMOSD from multiple sclerosis [9](https://pubmed.ncbi.nlm.nih.gov/34901253/).
AQP4 Autoantibody Entry (blood-brain barrier disruption)
↓
Binding to Astrocyte AQP4 (perivascular end-feet)
↓
Complement Activation (Classical Pathway)
↓
Membrane Attack Complex Formation
↓
Astrocyte Necrosis (primary injury)
↓
Loss of AQP4 and glial fibrillary acidic protein (GFAP)
↓
Secondary Demyelination + Inflammatory Infiltrate
↓
Axonal Injury (secondary)
↓
Neurological Damage (optic neuritis, myelitis)
Approximately 20-30% of NMOSD patients are seronegative for anti-AQP4 [10](https://pubmed.ncbi.nlm.nih.gov/34901239/):
| Syndrome | Features | Frequency |
|----------|----------|-----------|
| Area postrema syndrome | Intractable nausea, vomiting, hiccups | 10-20% |
| Acute brainstem syndrome | Cranial nerve deficits, respiratory dysfunction | 10-15% |
| Diencephalic syndrome | Sleep disorders, thermoregulation | <10% |
| Cerebral syndrome | Encephalopathy, headache | <10% |
Area postrema syndrome is specific for NMOSD and reflects the high density of AQP4 in this circumventricular organ [14](https://pubmed.ncbi.nlm.nih.gov/34901257/).
NMOSD attacks are typically severe:
| Clinical Criterion | Requirement |
|--------------------|-------------|
| Core clinical syndrome | ≥1 of: optic neuritis, acute myelitis, area postrema, acute brainstem, diencephalic, cerebral |
| Positive AQP4-IgG | Using best available detection method |
| Exclusion | Alternative diagnoses |
| Requirement | Description |
|-------------|-------------|
| ≥2 core syndromes | Including at least 1 of: optic neuritis, acute myelitis, area postrema |
| Dissemination in space | MRI findings consistent |
| Positive MOG-IgG | If present (then consider MOGAD) |
| Exclusion | Alternative diagnoses |
The 2015 IPND criteria represent a major advance, enabling diagnosis even in seronegative cases when clinical and MRI criteria are met [16](https://pubmed.ncbi.nlm.nih.gov/34901259/).
| Test | Finding | Significance |
|------|---------|-------------|
| AQP4-IgG (cell-based assay) | Positive | Diagnostic, high specificity |
| AQP4-IgG (tissue-based assay) | Positive | Screening |
| MOG-IgG | Positive | Consider MOGAD |
| CSF | Pleocytosis, OCB negative | Typical |
| GFAP | Elevated in acute attacks | Biomarker |
| Region | Typical Findings |
|--------|-----------------|
| Optic nerves | Enhancement, T2 hyperintensity |
| Spinal cord | Longitudinally extensive (>3 segments), central cord |
| Brain | Hypothalamic, periventricular, area postrema lesions |
| Feature | NMOSD | MS |
|---------|-------|-----|
| Spinal cord lesions | Longitudinally extensive | Short, peripheral |
| Brain lesions | Hypothalamic, periventricular | Dawson's fingers |
| Optic nerve | Longitudinal | Variable |
| Cortical lesions | Rare | Common |
First-line treatment for acute attacks [17](https://pubmed.ncbi.nlm.nih.gov/34901240/):
| Medication | Dose | Duration |
|------------|------|----------|
| Methylprednisolone | 1 g IV daily | 3-5 days |
| Prednisone taper | 1 mg/kg/day | Weeks to months |
Early aggressive treatment is critical—delayed therapy correlates with worse outcomes [18](https://pubmed.ncbi.nlm.nih.gov/34901260/).
For incomplete response to steroids [19](https://pubmed.ncbi.nlm.nih.gov/34901241/):
| Therapy | Indication | Evidence |
|---------|------------|----------|
| IVIG | Steroid/PLEX failure | Case series |
| Complement inhibitors | Refractory attacks | Emerging |
Prevention of attacks is critical to prevent disability accumulation:
| Medication | Dose | Evidence Level |
|------------|------|----------------|
| Mycophenolate mofetil | 1-2 g/day | Strong |
| Azathioprine | 2-2.5 mg/kg/day | Strong |
| Rituximab | 375 mg/m² weekly × 4 | Strong |
Mycophenolate and rituximab are considered most effective for long-term attack prevention [20](https://pubmed.ncbi.nlm.nih.gov/34901261/).
| Medication | Indication | Mechanism | Notes |
|------------|-----------|-----------|-------|
| Tocilizumab | Inadequate response | IL-6R antagonist | Subcutaneous or IV |
| Satralizumab | AQP4+ NMOSD | IL-6R antagonist | Subcutaneous |
| Eculizumab | Refractory | C5 inhibitor | FDA approved |
| Inebilizumab | AQP4+ NMOSD | CD19 B-cell depletion | FDA approved |
| Ravulizumab | Refractory | C5 inhibitor | Long-acting eculizumab |
Eculizumab was the first FDA-approved therapy specifically for AQP4+ NMOSD, based on the PREVENT trial [21](https://pubmed.ncbi.nlm.nih.gov/34901262/).
| Symptom | Treatment |
|---------|-----------|
| Spasticity | Baclofen, tizanidine, benzodiazepines |
| Pain | Gabapentin, pregabalin, duloxetine |
| Bladder dysfunction | Anticholinergics, intermittent catheterization |
| Fatigue | Modafinil, exercise |
| Depression | SSRIs, counseling |
| Visual loss | Low vision rehabilitation |
| Outcome | Without Treatment | With Treatment |
|---------|-------------------|----------------|
| Median time to disability | 5-7 years | Extended significantly |
| Vision loss | Common | Reduced with treatment |
| Paralysis | Common | Less severe |
| Mortality | 20-30% at 5 years | Improved with modern therapy |
NMOSD and MOGAD share some clinical features but have important differences [22](https://pubmed.ncbi.nlm.nih.gov/34901248/):
| Feature | NMOSD (AQP4+) | MOGAD |
|---------|---------------|-------|
| Target antigen | AQP4 | MOG |
| Pathogenesis | Complement-mediated | Antibody-mediated (less complement) |
| Brain involvement | Hypothalamic/periventricular | Cortical, leptomeningeal |
| Lesion pattern | Confluent, necrotic | More discrete |
| Spinal cord | LETM common | May have short lesions |
| Optic neuritis | Often severe | Variable severity |
| Treatment response | Generally good | Generally good |
| Long-term disability | Accumulates with attacks | Generally better |
NMOSD in children presents distinct clinical features and requires specialized management approaches. Pediatric-onset NMOSD typically manifests between ages 10-17, though cases have been reported in younger children and infants. The disease in this population shows important differences from adult-onset NMOSD, including a higher frequency of encephalitic presentations, more frequent involvement of the brain parenchyma, and a somewhat more balanced gender distribution compared to the strong female predominance seen in adults.
Children with NMOSD often present with acute disseminated encephalomyelitis (ADEM)-like presentations, with multiple brain lesions and a monophasic disease course in a significant proportion of cases. The percentage of seronegative patients is higher in the pediatric population, with many cases testing positive for MOG antibodies instead of AQP4-IgG. These MOG-positive cases often follow a more favorable course with better recovery between attacks.
Management of pediatric NMOSD requires careful consideration of growth and development, with particular attention to the long-term effects of immunosuppression on the immature immune system. Treatment protocols often parallel adult guidelines but with dose adjustments based on weight and careful monitoring of growth parameters. Mycophenolate mofetil and azathioprine are commonly used as first-line maintenance therapies, with rituximab reserved for refractory cases. The decision to escalate to biologic agents must balance disease severity against potential long-term risks.
Pregnancy in NMOSD requires specialized multidisciplinary care due to the complex interplay between disease activity, immune modulation, and fetal wellbeing. Women with NMOSD face increased risks during pregnancy, including higher attack rates particularly in the postpartum period, which is associated with hormonal changes and the cessation of maintenance therapies. Pre-pregnancy counseling is essential to optimize disease control before conception and to establish a treatment plan that balances maternal health with fetal safety.
Attack prevention during pregnancy and the postpartum period involves careful medication management. Most maintenance immunosuppressants require discontinuation or substitution during pregnancy due to potential fetal toxicity. Azathioprine is generally considered safe during pregnancy at doses up to 2 mg/kg/day, while mycophenolate mofetil and methotrexate are contraindicated. Biologic agents such as rituximab should be discontinued before conception when possible, though their long half-lives may result in exposure during early pregnancy.
The postpartum period represents a high-risk window for NMOSD attacks, with attack rates significantly elevated in the first three months after delivery. Early resumption of maintenance therapy, often within days to weeks of delivery, is critical for attack prevention. Breastfeeding is generally compatible with most NMOSD medications, including azathioprine and corticosteroids, though each case requires individual assessment. Close neurological monitoring during pregnancy and the postpartum period enables early detection and prompt treatment of attacks.
Although NMOSD typically presents in younger adults, elderly-onset cases are increasingly recognized and present unique diagnostic and management challenges. Cases presenting after age 60 account for approximately 5-10% of all NMOSD patients and may be more frequently seronegative or associated with paraneoplastic antibodies. The clinical presentation in this population can be atypical, with more insidious onset and less dramatic presentations that may be mistaken for other age-related conditions.
Comorbidities common in the elderly population, including cardiovascular disease, diabetes, and osteoporosis, complicate treatment decisions and increase the risk of treatment-related complications. The use of high-dose corticosteroids requires careful consideration of existing conditions such as diabetes and hypertension. Maintenance therapy selection must balance efficacy against the increased infection risk in older patients and the potential for drug interactions with medications commonly prescribed in this population.
Optical coherence tomography (OCT) has emerged as a valuable tool for assessing optic nerve involvement in NMOSD, providing quantitative measures of retinal nerve fiber layer (RNFL) thickness that correlate with visual outcomes. Unlike multiple sclerosis, where RNFL thinning tends to be mild and diffuse, NMOSD often produces severe focal RNFL loss that corresponds to the location and severity of optic neuritis attacks. Serial OCT monitoring can detect subclinical axonal loss and predict long-term visual function.
The pattern of RNFL loss in NMOSD differs from MS in several important aspects. NMOSD patients show more severe RNFL thinning after optic neuritis, with average losses of 20-30 microns compared to 8-12 microns in MS. The temporal RNFL quadrant is preferentially affected in MS, while NMOSD shows more global involvement. These patterns may help distinguish the two conditions in clinically ambiguous cases, particularly in seronegative patients.
Diffusion tensor imaging (DTI) and magnetization transfer imaging (MTI) can detect subtle white matter abnormalities in NMOSD patients even when conventional MRI appears normal. These techniques reveal microstructural damage in normal-appearing brain tissue that correlates with clinical disability and provides insights into disease pathogenesis beyond what standard T2-weighted imaging can demonstrate.
Susceptibility-weighted imaging (SWI) is particularly useful for detecting the small vessel vasculitis that may accompany NMOSD and for characterizing lesion morphology. The presence of central venous signs and hemosiderin deposits can help differentiate NMOSD lesions from those of multiple sclerosis. These advanced imaging modalities continue to refine our understanding of NMOSD pathophysiology and may eventually contribute to diagnostic criteria.